Phase 3 Myasthenia Gravis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Your blood tests show specific antibodies linked to myasthenia gravis (called AChR or MuSK antibodies)
• Your myasthenia gravis has been rated as moderate to severe by your doctor (classified as MGFA Class II–IV)
• Your symptoms score at least 6 out of 24 on a standard daily activities questionnaire at the start of the study
• Your muscle weakness scores at least 11 out of 39 on a standard strength test at the start of the study
• You have tried at least 2 immune-suppressing treatments that did not work well enough, OR tried at least 1 and also needed regular plasma exchange or immunoglobulin infusions to manage your symptoms
• You have been on a stable dose of steroids or other immune treatments for at least 1 month before screening (or at least 2 months if you take azathioprine)
• Your dose of muscle-strength medication (such as pyridostigmine) has not changed in the last 2 weeks before screening
• You have not had an immunoglobulin infusion or plasma exchange in the 4 weeks before screening (unless it is part of your regular ongoing treatment)
• You have not received rituximab or similar antibody treatments in the 12 weeks before screening
• You are able and willing to attend all required visits at the study site

Who may not be able to join:

• You are unable to temporarily stop certain autoimmune treatments before the study procedures if required
• You have another nerve or muscle condition alongside myasthenia gravis, such as Lambert-Eaton syndrome, myositis, or motor nerve disease
• You have a history of stroke with lasting effects or risk of recurrence, seizures, a degenerative brain condition, unexplained changes in mental status, or severe uncontrolled psychiatric illness
• You have a serious uncontrolled medical condition — such as a significant heart or lung disease — that the study doctor believes could put you at risk or interfere with the study
• You have a history of a primary immune deficiency, an organ or bone marrow transplant, or have had your spleen removed
• You have an active or uncontrolled infection (viral, bacterial, or fungal), or a history of frequent repeated infections
• You had your thymus removed less than 12 months before screening, or plan to have it removed during the study
• You have previously received gene therapy or a cell-based immune treatment such as CAR-T therapy
• You require ongoing blood-thinning (anticoagulant) medication that cannot be safely stopped for medical procedures

Important: Always verify eligibility with the trial site directly before applying.